Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339316 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL1899979 | 0.73 | — | — | |
| SCHEMBL421623 | 0.69 | CRBN (0.32) | — | |
| SCHEMBL11087183 | 0.69 | — | — | |
| SCHEMBL34460214 | 0.67 | — | — | |
| SCHEMBL5265997 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL7545038 | 0.67 | — | — | |
| SCHEMBL34460307 | 0.67 | — | — | |
| SCHEMBL10757720 | 0.67 | — | — | |
| SCHEMBL15832528 | 0.67 | HDAC8 (0.30) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | claimed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | claimed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | claimed |
| EP-2268624-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | claimed |
| CN-118772131-A | Biaryl compound and preparation method and application thereof | 河南大学 | 2024-10-15 | — | — | CN | disclosed |
| EP-2152254-B1 | RESVERATROL CONTAINING COMPOSITION FOR MODULATING BONE FORMATION | UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) | 2017-11-22 | — | — | EP | disclosed |
| EP-2711361-B1 | NITROGENATED HETEROCYCLIC COMPOUND AND AGRICULTURAL OR HORTICULTURAL FUNGICIDE | NIPPON SODA CO (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9060517-B2 | Nitrogenated heterocyclic compound and agricultural or horticultural fungicide | NIPPON SODA CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-5393654-A | Heptamethine cyanine dyes in which both nitrogen atoms of the cyanine chromophore bear a carboxyalkyl substituent | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0631176-A1 | Photothermographic materials | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5374514-A | Photographic silver halide, reducible silver source, reducing agent, binder, specific antifoggant and/or image stabilizer | CARESTREAM DENTAL LLC | 1994-12-20 | — | — | US | disclosed |
| EP-0616014-A2 | Photothermographic imaging materials and sensitisers therefor | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-09-21 | — | — | EP | disclosed |
| CN-1089943-A | Light heat sensitive imaging material | MINNESOTA MINING & MFG (US) | 1994-07-27 | — | — | CN | disclosed |
| EP-0605981-A1 | Photothermographic materials | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-07-13 | — | — | EP | disclosed |
| EP-0600587-A1 | Photothermographic imaging materials and antifoggants therefor | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | IAPP, GPR119, GLP1R | HDAC8 1593/4885 |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, GPR119, IAPP | HDAC8 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.